Results 21 to 30 of about 309,141 (294)

A nomogram model for predicting distant metastasis of newly diagnosed colorectal cancer based on clinical features

Frontiers in Oncology, 2023
ObjectiveColorectal cancer is one of the most common primary malignancies and the third most common cause of cancer death in both men and women in the United States.
Jiang-Hua He, Cong Cao, Yang Ding, Yun Yi, Yu-Qing Lv, Chun Wang, Ying Chang   +6 more
doaj   +1 more source

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. [PDF]

, 2017
INTRODUCTION: Colorectal cancer remains the second leading cause of cancer death in the United States, and new strategies to prevent, detect, and treat the disease are needed.
Aka, Allison A., Pattison, Amanda M., Rappaport, Jeff A., Sato, Takami, Snook, Adam E., Waldman, Scott A.   +5 more
core   +2 more sources

EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer

Scientific Reports, 2022
Due to the difficulty in sampling of metastatic tumors, patient selection is commonly based on results of primary tumor samples when metastatic samples are not available.
Peng Ye, Fanghua Li, Yuanyuan Wei, Yihao Zhang, Jianing Cui, Rui Dai, Hao Chen, Jing Xie, Peiling Cai   +8 more
doaj   +1 more source

Systemic treatment of advanced colorectal cancer with particular emphasis on the treatment methods reimbursed in Poland. [PDF]

Farmacja Polska, 2022
Colorectal cancer is a leading cause of cancer deaths worldwide. The number of patients diagnosed with the disease continues to increase. Approximately 20% of patients are diagnosed with metastatic disease, while in 35% of patients, metastatic relapse ...
Marta Szumilak
doaj   +1 more source

The importance of circulating tumor products as „liquid biopsies” in colorectal cancer [PDF]

, 2018
Liquid biopsies represent an array of plasma analysis tests that are studied to evaluate and identify circulating tumor products, especially circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).
Calborean, Veronica, Miscoci, Alina, Pirvu, Cristian D., Pădureanu, Vlad, Rogoveanu, Otilia C., Streba, Costin T., Vere, Cristin C.   +6 more
core   +4 more sources

Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer

Frontiers in Genetics, 2021
Liquid biopsy, which generally refers to the analysis of biological components such as circulating nuclear acids and circulating tumor cells in body fluids, particularly in peripheral blood, has shown good capacity to overcome several limitations faced ...
Wei Gao, Yigui Chen, Jianwei Yang, Changhua Zhuo, Sha Huang, Hui Zhang, Yi Shi   +6 more
doaj   +1 more source

Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors [PDF]

, 2019
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic ...
Aderka, Dan, García Foncillas, Jesús, Ronga, Philippe, Stintzing, Sebastian, Sunakawa, Yu, Wainberg, Zev, Witzler, Pauline   +6 more
core   +1 more source

Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials [PDF]

, 2012
Purpose: This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC).
Allegra CJ, Amado RG, Andreas Jung, Andreyev HJ, Bazan V, Bokemeyer C, Bos JL, Boughdady IS, Cappuzzo F, Cerottini JP, Christoph C. Zielinski, De Roock W, Dominik P. Modest, Douillard JY, Finkelstein SD, Frattini M, Galina Kurteva, Heinemann V, Janja Ocvirk, Jens Neumann, Jonker DJ, Karapetis CS, Khambata-Ford S, Khosravi-Far R, Lièvre A, Maughan TS, Moosmann N, Neumann J, Ocvirk J, Regina Knittelfelder, Roth AD, Ruediger P. Laubender, Samowitz WS, Scheffzek K, Sebastian Stintzing, Thomas Brodowicz, Thomas Kirchner, Tournigand C, Tveit K, Van Cutsem E, Volker Heinemann, Zsuzsanna Papai   +41 more
core   +1 more source

The Role of Circulating Tumour Cells and Carcinoembryonic Antigen as Diagnostic Tool for Metastatic Colorectal Cancer in Indonesia

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Background: Patients with metastatic colorectal cancer (CRC) have a poor prognosis, with a 5-year survival rate of only 14%. Early detection and early intervention may improve outcome.
Sri Angraeni, Murdani Abdullah, Irsan Hasan, Ikhwan Rinaldi, Achmad Fauzi, Cleopas Martin, Hamzah Shatri, Cosphiadi Irawan, Saskia Aziza Nursyirwan, Febiansyah Ibrahim, Lianda Siregar, Imelda Maria Loho, Agus Sudiro Waspodo, Ariansah Margaluta, Fajar Firsyada, Nikko Darnindro, Evah Lutfiah, Caroline Tanadi, Mohammad Ilyas   +18 more
doaj   +1 more source